MétaCan
Menu
Back to cohort
Record W4406958948 · doi:10.1093/ehjci/jeae333.450

Can flax "milk" prevent chemotherapy mediated cardiotoxicity in women with breast cancer?

2025· article· en· W4406958948 on OpenAlexaff
Davinder S. Jassal, Vibhuti Arya, Lana Mackic, Sara M. Telles-Langdon, David Cheung, Allison Ledingham, Paris R. Haasbeek, Danielle Desautels, Vinessa Gordon, Jonathon J. Graham, Susan Green, Debjani Grenier, Chang H. Kim, Molly E.W. Thiessen, Marshall Pitz

Bibliographic record

VenueEuropean Heart Journal - Cardiovascular Imaging · 2025
Typearticle
Languageen
FieldMedicine
TopicChemotherapy-induced cardiotoxicity and mitigation
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsCardiotoxicityBreast cancerMedicineChemotherapyOncologyInternal medicineCancerCancer chemotherapy

Abstract

fetched live from OpenAlex

Abstract Introduction Cardio-oncology focuses on the prevention, diagnosis, and management of cancer patients who are at risk of developing cardiovascular complications as a result of their anti-cancer treatment. Amongst the various pharmacological therapies which may prevent anthracycline mediated cardiotoxicity in women with breast cancer, including renin-angiotensin system (RAS) antagonists, beta blockers, and statins, there has been an increased interest on the role of nutraceuticals in this setting. Although we recently demonstrated the cardioprotective role of dietary flaxseed (FLX) in the prevention of adverse cardiovascular remodeling in a chronic in vivo female murine model of anthracycline mediated cardiotoxicity, little is known on the effects of this dietary agent in the clinical setting. Purpose The aim of the "Can flax "milk" prevent chemotherapy mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)" study was to investigate whether consumption of FLX "milk" can prevent cardiac dysfunction in women with breast cancer treated with anthracyclines. Methods In this double-blinded, single centre, prospective randomized controlled clinical trial, women with breast cancer were randomized to oral consumption of either placebo oat fiber "milk" or FLX "milk" [each containing 30 grams of oat or flaxseed, respectively] for a total of 4 months while receiving anthracycline-based chemotherapy. Serial echocardiography was performed at baseline, 4-month, and 6-month follow-up. Results Between September 2021 and December 2023, a total of 21 women with early-stage breast cancer (EBC) (mean age 48±10 years, BMI 28±5 kg/m2) were enrolled in the CANFLAX-BC study. During the 4-month intake period, a total of 8 women received oat fibre "milk" and 13 women received FLX "milk", with a comparable adherence rate of approximately 70% for both groups. At baseline, 4-month, and 6-month follow-up, the LVEF was 68±4%, 69±3%, 66±4% for the oat fibre "milk" group, and 67±5%, 68±4%, 66±5% for the FLX "milk" group (no significant difference; Table 1, Figure 1A). Although the mean global longitudinal strain (GLS) was comparable between both groups at baseline, the GLS was significantly lower at -13.8±0.3% (4 months) and -15.1±0.3% (6 months) for the oat fibre "milk" group, as compared to a preserved GLS of -18.4±0.3% (4 months) and -18.5±0.2% (6 months) for the FLX "milk group (*p<0.05; Table 1, Figure 1B). Conclusion In women receiving anthracycline based chemotherapy for breast cancer, FLX "milk" consumption prevents early cardiotoxicity, as reflected by the preservation of GLS parameters. Table 1 Figure 1

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.676
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.253
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal - Cardiovascular ImagingSame topicChemotherapy-induced cardiotoxicity and mitigationFrench-language works237,207